Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Allergy Clin Immunol. 2019 Sep 25;144(6):1566–1574.e6. doi: 10.1016/j.jaci.2019.08.040

Figure 1.

Figure 1.

Levels of TATc and TAFI in nasal lavage fluids and nasal tissue. (A) Increased TATc in nasal lavage fluids in patients with CRS compared to controls (●; control, ■; CRSsNP, ▲; CRSwNP in nasal lavage fluids, n = 15–21). (B) The level of TATc in nasal polyp tissue is increased compared to all UT (●; control UT, ■; CRSsNP UT, ▲; CRSwNP UT, △; CRSwNP NP tissue, n = 7 − 15). (C)) Increased TAFI in nasal lavage fluids in CRSwNP (n = 15–21). (D) Increased TAFI levels were observed in nasal polyp tissue compared to all UT tissue (n = 7 − 15). The levels of TATc and TAFI protein in nasal lavage fluids and nasal tissue extract were measured by ELISA. The concentrations of TATc and TAFI were normalized to the concentration of total protein. *P < .05, **P < .01, and ***P < .001.